Efficacy of anti-tumor necrosis factor polyclonal antibody on phosphoenolpyruvate carboxykinase expression in septic and endotoxemic rats

Shock

Volumn 6, Issue 1, 1996, Pages 57-60

  Chang, Cheow K ^a   Gatan, Marlene ^a   Schumer, William ^a  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; LIPOPOLYSACCHARIDE; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTICLE; BIOSYNTHESIS; CECUM; DRUG EFFECT; ENDOTOXEMIA; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GLUCOSE BLOOD LEVEL; GLYCOGEN LIVER LEVEL; IMMUNOLOGY; LIVER; MALE; METABOLISM; PASSIVE IMMUNIZATION; PERITONITIS; RAT; SEPSIS; SPRAGUE DAWLEY RAT; TIME;

ANIMALS; ANTIBODIES; BLOOD GLUCOSE; CECUM; ENDOTOXEMIA; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; IMMUNIZATION, PASSIVE; LIPOPOLYSACCHARIDES; LIVER; LIVER GLYCOGEN; MALE; PERITONITIS; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); RATS; RATS, SPRAGUE-DAWLEY; SEPSIS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030184573     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-199607000-00012     Document Type: Article

References (38)

1. Fry DE, Pearlstein L, Fulton RL, Polk HC Jr: Multiple system organ failure. Arch Surg 115:136-140, 1980.
2. Kreger BE, Craven DE, Carling PC, McCabe WR: Gram-negative bacteremia. III. Reassessment of etiology, epidemiology and ecology in 612 patients. Am J Med 68:332-343, 1980.
3. Fischer E, Marano MA, Barber AE, et al: Comparison between effects of interleukin-1α administration and sublethal endotoxemia in primates. Am J Physiol 261:R442-R452, 1991.
4. Del Rey A, Besedovsky H: Interleukin 1 affects glucose homeostasis. Am J Physiol 253:R794-R798, 1987.
5. Vogel SN, Henricson BE, Neta R: Roles of interleukin-1 and tumor necrosis factor in lipopolysaccharide-induced hypoglycemia. Infect Immun 59:2494-2498, 1991.
6. Bauss F, Droge W, Mannel DN: Tumor necrosis factor mediates endotoxic effects in mice. Infect Immun 55:1622-1625, 1987.
7. Henricson BE, Benjamin WR, Vogel SN: Differential cytokine induction by doses of lipopolysaccharide and monophosphoryl lipid A that result in equivalent early endotoxin tolerance. Infect Immun 58:2429-2437, 1990.
8. Zanetti G, Heumann D, Gerain J, et al: Cytokine production after intravenous or peritoneal Gram-negative bacterial challenge in mice. J Immunol 148:1890-1897, 1992.
9. Dinarello CA, Cannon JG, Wolff SM, et al: Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 163:1433-1450, 1992.
10. Tracey KJ, Beutler B, Lowry SF, et al: Shock and tissue injury induced by recombinant human cachectin. Science 234:470-474, 1986.
11. Emerson TE Jr, Lindsey DC, Jesmok GJ, Duerr ML, Fournel MA: Efficacy of monoclonal antibody against tumor necrosis factor alpha in an endotoxemic baboon model. Circ Shock 38:75-84, 1992.
12. Beutler B, Milsark LW, Cerami AC: Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229:869-871, 1985.
13. Mathison JC, Wolfson E, Ulevitch RJ: Participation of tumor necrosis factor in the mediation of Gram-negative bacterial lipopolysaccharide-induced injury in rabbits. J Clin Invest 81:1925-1937, 1988.
14. Tracey KJ, Fong Y, Hesse DG, et al: Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330: 662-664, 1987.
15. Chang CK, Moskal SF II, Srivenugopal KS, Schumer W: Altered levels of mRNA encoding enzymes of hepatic glucose metabolism in septic rats. Circ Shock 41:35-39, 1993.
16. National Institutes of Health: Guide for the Care and Use of Laboratory Animals. Bethesda MD: National Institutes of Health Publication No. 93-23, 1995, pp 1-83.
17. Deutschman CS, De Maio A, Clemens MG: Sepsis-induced attenuation of glucagon and 8-BrcAMP modulation of the phosphoenolpyruvate carboxykinase gene. Am J Physiol 269:R584-R591, 1995.
18. Lamers WH, Hanson RW, Meisner HM: cAMP stimulates transcription of the gene for cytosolic phosphoenolpyruvate carboxykinase in rat liver nuclei. Proc Natl Acad Sci USA 79:5137-4141, 1982.
19. Passoneau JV, Lauderdale VR: A comparison of three methods of glycogen measurement in tissues. Anal Biochem 60:405-412, 1974.
20. Hill M, McCallum R: Altered transcriptional regulation of phosphoenolpyruvate carboxykinase in rats following endotoxin treatment. J Clin Invest 88:811-816, 1991.
21. Pilkis SJ, Granner DK: Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis. Annu Rev Physiol 54:885-909, 1992.
22. Zabala MT, Lorenzo P, Alvarez L, Berlanga JJ, Garcia-Ruiz JP: Serotonin increases the cAMP concentration and the phosphoenolpyruvate carboxykinase mRNA in rat kidney, small intestine, and liver. J Cell Physiol 150:451-455, 1992.
23. Rosella G, Zajac JD, Kaczmarczyk SJ, Andrikopoulos S, Proietto J: Impaired suppression of gluconeogenesis induced by overexpression of a noninsulin-responsive phosphoenolpyruvate carboxykinase gene. J Mol Endocrinol 7:1456-1462, 1993.
24. Hill MR, McCallum RE: Identification of tumor necrosis factor as a transcriptional regulator of the phosphoenolpyruvate carboxykinase gene following endotoxin treatment of mice. Infect Immun 60:4040-4050, 1992.
25. Deutschman CS, De Maio A, Buchman TG, Clemens MG: Sepsis-induced alterations in phosphoenolpyruvate carboxykinase expression: The role of insulin and glucagon. Circ Shock 40:295-302, 1993.
26. Goto M, Zeller WP, Lichtenberg RC: Decreased gluconeogenesis and increased glucose disposal without hyperinsulinemia in 10 day old rats with endotoxic shock. Metabolism 43:1248-1254, 1994.
27. Wang K, Deutschman CS, Clemens MG, De Maio A: Reciprocal expression of phosphoenolpyruvate carboxykinase and acute phase gene during acute inflammation. Shock 3:204-209, 1995.
28. Kuttner RE, Ebata T, Apantaku FO, Schumer W: The influence of glucocorticoids on hepatic glycolytic intermediates in fed peritonitis rats. Adv Shock Res 10:175-182, 1983.
29. Lundblad R, Sandven P, Giercksky K-E: The physical nature of a large bowel perforation predicts severity of the subsequent inflammatory response. Shock 3:455-461, 1995.
30. Stith RD, McCallum RE: Failure of glucagon to induce hepatic phosphoenolpyruvate carboxykinase in endotoxic shock. Circ Shock 26:267-272, 1988.
31. Ertel W, Morrison MH, Wang P, Zheng F, Ayala A, Chaudry IH: The complex pattern of cytokines in sepsis: Association between prostaglandins, cachectin, and interleukins. Ann Surg 214:141-148, 1991.
32. Eskandari MK, Bolgos G, Miller C, Nguyen DT, DeForge LE, Remick DG: Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J Immunol 148:2724-2730, 1992.
33. Astiz M, Rackow EC, Weil MH, Schumer W: Early impairment of oxidative metabolism and energy production in severe sepsis. Circ Shock 26:311-320, 1988.
34. Astiz M, Rackow EC, Weil MH, Schumer W: Impaired hepatic energy production during septic shock. Circ Shock 21:300, 1987 (abstract #21).
35. Bagby GJ, Plessala KJ, Wilson LA, Thompson JJ, Nelson S: Divergent efficacy of antibody to tumor necrosis factor-α in intravascular and peritonitis models of sepsis. J Infect Dis 163:83-88, 1991.
36. Remick D, Manohar P, Bolgos G, Rodriguez J, Moldawer L, Wollenber G: Blockade of tumor necrosis factor reduces lipopolysaccharide lethality, but not the lethality of cecal ligation and puncture. Shock 4:89-95, 1995.
37. Fisher CJ Jr and members of the CB0006 Sepsis Syndrome Study Group: Influence of anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 21:318-327, 1993.
38. Abraham E and members of the TNF-α mAb Sepsis Study Group: Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome. J Am Med Assoc 273:934-941, 1995.